Subscribe 600$/product give away!
Submit an Article to Pharmacy HQ     
Please include the author's name, title, and citations.     

CAMPATH- alemtuzumab injection

Patient Information

Cytopenias: Advise patients to report any signs or symptoms such as bleeding, easy bruising, petechiae or purpura, pallor, weakness or fatigue[seeWarnings and Precautions (5.1)andAdverse Reactions (6.1)].

Infusion Reactions: Advise patients of the signs and symptoms of infusion reactions and of the need to take premedications as prescribed[seeWarnings and Precautions (5.2)andAdverse Reactions (6.1)].

Infections: Advise patients to immediately report symptoms of infection (e.g. pyrexia) and to take prophylactic anti-infectives for PCP (trimethoprim/sulfamethoxazole DS or equivalent) and for herpes virus (famciclovir or equivalent) as prescribed[seeWarnings and Precautions (5.3)andAdverse Reactions (6.1)].

Advise patients that irradiation of blood products is required[seeWarnings and Precautions (5.3)].

Advise patients that they should not be immunized with live viral vaccines if they have recently been treated with CAMPATH[seeWarnings and Precautions (5.5)].

Advise male and female patients with reproductive potential to use effective contraceptive methods during treatment and for a minimum of 6 months following CAMPATH therapy[seeNonclinical Toxicology (13.1)].

Manufactured and distributed by:
Genzyme Corporation, Cambridge, MA 02142

CAMPATH is a registered trademark of Genzyme Corporation.

2018 Genzyme Corporation.

Your use of this website constitutes your agreement to the terms and conditions linked below:
Terms and Conditions | Resources | Sitemap
2017 © Copyright Questions?
Please contact: